ArticleJournal of market access & health policy2017
The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change.
Article in Journal of market access & health policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.Frontiers in public health · 2019Pooled it
- The European Union's Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks.Journal of market access & health policy · 2026Article
- Balancing Innovation and Access: Insights from AIM's Fair Pricing Model and Its Current and Future Applications.PharmacoEconomics · 2026Article
- Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe.Journal of community genetics · 2026Review
- Evolution and synergy of healthcare security policies for rare diseases in China: a quantitative content analysis.Frontiers in public health · 2026Article
- Debates over orphan drug pricing: a meta-narrative literature review.Orphanet journal of rare diseases · 2025Review
- Values, challenges, and responses associated with high-priced potential cures: perspectives of diverse stakeholders in South Korea.Cost effectiveness and resource allocation : C/E · 2024Article
- Inequities in kidney health and kidney care.Nature reviews. Nephrology · 2023Review
- Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.International journal of environmental research and public health · 2023Review
- Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010-2019.Frontiers in pharmacology · 2022Article
- Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications.Frontiers in pharmacology · 2022Article
- Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.Healthcare (Basel, Switzerland) · 2021Article
- A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe.Frontiers in pharmacology · 2021Review
- Public spending on orphan medicines: a review of the literature.Journal of pharmaceutical policy and practice · 2020Article
- Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.Frontiers in pharmacology · 2020Article
- Non-profit drug research and development: the case study of Genethon.Journal of market access & health policy · 2019Article
- Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.